|
subsections menu :
Contacts
|
Content :
Press releases 2007
December 13, 2007 Taxotere®-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy In Early Stage Breast Cancer
December 10, 2007 New anti-thrombotic compound AVE5026 shows highly significant dose response in TREK phase IIb study
December 3, 2007 Sanofi-aventis inaugurates first Asian development centre for pharmaceuticals in Goa, India
November 30, 2007 Sanofi-aventis and Astellas to restructure the joint venture activities in Japan of Fujisawa sanofi-aventis K.K.
November 29, 2007 Sanofi-aventis initiates a major global collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19 %
November 26, 2007 Sanofi-aventis to build a vaccine facility in Shenzhen for prevention of influenza and pandemic readiness in China
November 16, 2007 Rimonabant - Bibliographical update
November 13, 2007 Rimonabant - Regulatory Update in Europe
November 13, 2007 Sanofi Pasteur and Acambis join forces to bring West Nile vaccine to market
November 10, 2007 New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort® AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
November 7, 2007 Retrospective Analysis Finds that Initiation of Insulin Glargine in Patients with Type 2 Diabetes was Associated with a Lower Incidence Rate of Myocardial Infarction as Compared with NPH Insulin
November 7, 2007 Coarsucam™/“ASAQ” is as Effective as Coartem® in Treating Uncomplicated Malaria
November 7, 2007 Sanofi Pasteur initiates phase II trial of cell culture-based seasonal influenza vaccine
November 6, 2007 Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccine
October 31, 2007 Good third quarter performance: increase in 2007 full-year earnings growth guidance
October 24, 2007 Studies Showing Significant Survival Improvement with Taxotere®-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of The New England Journal of Medicine
October 24, 2007 New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR® (zolpidem tartrate extended-release) tablets
October 22, 2007 Taxotere® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for induction treatment for locally advanced Head and Neck cancer
October 22, 2007 Plavix® indications expanded in Japan to include patients with Acute Coronary Syndrome for whom percutaneous coronary intervention is being planned
October 18, 2007 Sanofi Pasteur receives FDA approval of meningococcal vaccine for children
October 15, 2007 Sanofi Pasteur and Institut Pasteur team up against malaria
October 2, 2007 New prescription allergy treatment XYZAL® (levocetirizine dihydrochloride) now available for fall allergy season in the USA
October 1, 2007 Taxotere® (docetaxel) granted FDA approval to treat Locally Advanced Head and Neck Cancer prior to chemoradiotherapy and surgery
September 24, 2007 Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World)
September 19, 2007 Appropriate glycemic control contributes to reducing the risk of macrovascular diseases in patients with diabetes
September 19, 2007 Rimonabant effectively reduces visceral fat in the obese patient as confirmed by abdominal computer tomography (CT) scan
September 17, 2007 A promising R&D portfolio, well positioned to deliver future growth
September 14, 2007 Sanofi-aventis initiates Research collaboration in China in the cancer stem-cell field
September 10, 2007 Sanofi-aventis announces settlement of Average Wholesale Price Civil Suits with the U.S. Department of Justice relating to Anzemet®
September 5, 2007 The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With No Observed Pro-Arrhythmia
September 4, 2007 Survival Benefit of Taxotere®-Based Regimens In Patients With Non Small Cell Lung Cancer
September 3, 2007 New Study Findings Confirm CLEXANE®/LOVENOX® Long-Term Clinical Benefit In Patients Suffering From Acute Coronary Syndrome
August 2, 2007 Availability on line of the Group’s half-year financial report for 2007
August 1, 2007 First half: solid results in a difficult context. Plavix® recovers its position in the US, full impact expected in H2
July 26, 2007 Sanofi pasteur President and CEO David J. Williams to retire; Wayne Pisano named President and CEO
July 20, 2007 Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facility
July 19, 2007 CHMP approves labelling update of Acomplia® in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression
July 11, 2007 Idraparinux shows encouraging results in the prevention of thromboembolic events in patients with atrial fibrillation
July 8, 2007 New study shows that extending prophylaxis with Clexane®/ Lovenox® (enoxaparin sodium injection) to 5 weeks is more effective than 10 days for reducing the risk of venous thromboembolism (VTE) in acutely ill medical patients with reduced mobility
July 4, 2007 Plavix® (clopidogrel bisulfate) receives priority review in Japan for supplemental new drug application (sNDA) for The treatment of acute coronary syndrome
June 29, 2007 Rimonabant Regulatory Update in the United States
June 29, 2007 Rimonabant Regulatory Update in Europe
June 27, 2007 Taxotere® (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery
June 24, 2007 Apidra® Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin And Oral Antidiabetic Treatments (BOT)
June 23, 2007 For any given level of HbA1c, Lantus® demonstrates less confirmed hypoglycemia over Insulin NPH
June 23, 2007 Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus® Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones
June 19, 2007 Sanofi-aventis and Bristol-Myers Squibb Prevail in U.S. Plavix® Patent Litigation
June 14, 2007 Sanofi pasteur awarded contract to retrofit influenza vaccine facility
June 13, 2007 FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factors
June 13, 2007 Sanofi pasteur supports WHO initiative for the establishment of an H5N1 vaccine stockpile
June 7, 2007 Taxotere® (docetaxel) receives Priority Review in Japan for Supplemental New Drug Application (sNDA) in prostate cancer
June 6, 2007 Sanofi-aventis at the 43rd annual 2007 ASCO meeting
June 6, 2007 Copaxone® pre-filled syringe can now be stored for up to one month at room temperature
June 4, 2007 Eloxatin® (oxaliplatin injection)-based chemotherapy sets new treatment benchmark in patients with metastatic colorectal cancer
June 4, 2007 The Eloxatin®-based regimen (FOLFOX4) significantly improved progression free survival when given before and after surgery in patients with resectable liver metastases from colorectal cancer
June 3, 2007 Oxford BioMedica and Sanofi-aventis report encouraging new TroVax® phase II trial results in renal cancer
June 3, 2007 S-1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S-1 alone
June 3, 2007 FOLFOX4 (Eloxatin®-based chemotherapy) after surgery improves overall survival in patients with early (stage III) colon cancer
June 3, 2007 “My child matters” one-year report program shows measurable improvement in cancer care for children in developing and newly industrialized countries
June 2, 2007 Encouraging results of VEGF Trap (Aflibercept) highlighted at ASCO 2007 annual meeting
May 31, 2007 Annual General Meeting
May 29, 2007 FDA approves XYZAL® tablets for the treatment of seasonal and year round allergies, and chronic urticaria
May 25, 2007 Data to be presented at ASCO 2007 highlights sanofi-aventis commitment to oncology
May 18, 2007 FDA approves Lovenox® (Enoxaparin Sodium Injection) for the most severe type of heart attack
May 15, 2007 Sanofi-aventis calls for an effective policy against drug counterfeiting
May 3, 2007 Full-year guidance raised on good 2007 first-quarter results
April 30, 2007 FDA Approves SoloSTAR® - A New Prefilled Disposable Insulin Pen For Use With LANTUS® In People With Type 1 And Type 2 Diabetes
April 26, 2007 Information relating to sanofi-aventis’ Combined General Meeting of May 31, 2007
April 26, 2007 Acomplia® (rimonabant) is approved in Brazil for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidemia
April 24, 2007 ACOMPLIA® (rimonabant) is reimbursed in Switzerland for the treatment of Type 2 Diabetics Overweight Patients and for the treatment of Patients with Obesity
April 20, 2007 The Lancet Publishes PREVAIL Study Results Showing Lovenox® Superiority Over Unfractionated Heparin For Reducing The Risk Of Venous Thromboembolism In Patients With Acute Ischemic Stroke
April 17, 2007 FDA Licenses First U.S. Vaccine for Humans Against Avian Influenza
April 3, 2007 Filing of the 2006 U.S. Form 20-F and French "Document de Référence"
April 3, 2007 Acomplia® (rimonabant) approved in Switzerland for the treatment of obese and overweight patients with at least one cardiovascular risk factor
April 2, 2007 Panaldine® commercial rights transferred from Daiichi to sanofi-aventis in Japan
March 30, 2007 Sanofi-aventis Announces Update To The European Summary Of Product Characteristics (SmPC) For Ketek® (telithromycin)
March 28, 2007 Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For Cancer
March 26, 2007 Rimonabant USA: Update
March 22, 2007 Acomplia® (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patients
March 16, 2007 LANTUS®SoloSTAR® and APIDRA®SoloSTAR® – New Disposable Insulin Pens for People with Type 1 and Type 2 Diabetes Will Be Launched Starting April 2007 in Europe
March 12, 2007 Sanofi-aventis' commitment to providing "Access to Medicines" in countries in the Southern Hemisphere shows real achievements
March 1, 2007 New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available
February 23, 2007 Taxotere® (docetaxel) significantly improves the survival of patients with advanced prostate cancer
February 14, 2007 Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine from Acambis
February 13, 2007 2006: In a difficult environment, another year of growth in adjusted EPS excluding selected items
February 12, 2007 Rimonabant USA: Update
February 12, 2007 Sanofi-aventis announces update to US Prescribing Information for Ketek® (telithromycin)
February 9, 2007 LOVENOX® patent infringement suit decided against Sanofi-aventis
February 6, 2007 FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack
February 6, 2007 Positive Recommendation for Acomplia® from the Transparency Committee in France
February 1, 2007 "My child matters": 26 programmes launched in 16 countries to fight childhood cancers
January 25, 2007 FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine
January 19, 2007 S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery alone
January 12, 2007 Sanofi-aventis intends to contest in court the decision to classify Acomplia® among non-reimbursable drugs in Germany
January 5, 2007 New Head of Research & Development at sanofi-aventis
|
Slots : |
Press releases and press packs are intended to journalists, investors and shareholders.
